148 related articles for article (PubMed ID: 38129745)
1. Mutations at proximal cysteine residues in PML impair ATO binding by destabilizing the RBCC domain.
Dubey S; Mishra N; Shelke R; Varma AK
FEBS J; 2024 Apr; 291(7):1422-1438. PubMed ID: 38129745
[TBL] [Abstract][Full Text] [Related]
2. Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients.
Lou Y; Ma Y; Sun J; Ye X; Pan H; Wang Y; Qian W; Meng H; Mai W; He J; Tong H; Jin J
Ann Hematol; 2015 Nov; 94(11):1829-37. PubMed ID: 26294332
[TBL] [Abstract][Full Text] [Related]
3. Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
Liu J; Zhu HH; Jiang H; Jiang Q; Huang XJ
Blood; 2016 Jan; 127(2):243-50. PubMed ID: 26537301
[TBL] [Abstract][Full Text] [Related]
4. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
[TBL] [Abstract][Full Text] [Related]
5. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
6. Multimodal approach to characterize the tetrameric form of human PML-RBCC domain and ATO-mediated conformational changes.
Dubey S; Mishra N; Goswami N; Siddiqui MQ; Varma AK
Int J Biol Macromol; 2022 Dec; 223(Pt A):468-478. PubMed ID: 36356867
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of PML-RARA Oncoprotein Targeting by Arsenic Unravels a Cysteine Rheostat Controlling PML Body Assembly and Function.
Bercier P; Wang QQ; Zang N; Zhang J; Yang C; Maimaitiyiming Y; Abou-Ghali M; Berthier C; Wu C; Niwa-Kawakita M; Dirami T; Geoffroy MC; Ferhi O; Quentin S; Benhenda S; Ogra Y; Gueroui Z; Zhou C; Naranmandura H; de Thé H; Lallemand-Breitenbach V
Cancer Discov; 2023 Dec; 13(12):2548-2565. PubMed ID: 37655965
[TBL] [Abstract][Full Text] [Related]
8. Identification of a point mutation PML
Zhao S; Shi P; Zhong Q; Shao S; Huang Y; Sun Y; Wu C; Zhu HH
Biochem Biophys Res Commun; 2019 Apr; 511(3):518-523. PubMed ID: 30824184
[TBL] [Abstract][Full Text] [Related]
9. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
[TBL] [Abstract][Full Text] [Related]
10. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Jo S; Lee YL; Kim S; Lee H; Chung H
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
[TBL] [Abstract][Full Text] [Related]
11. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
Marasca R; Zucchini P; Galimberti S; Leonardi G; Vaccari P; Donelli A; Luppi M; Petrini M; Torelli G
Haematologica; 1999 Nov; 84(11):963-8. PubMed ID: 10553155
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
13. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
14. Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemia.
Balasundaram N; Ganesan S; Chendamarai E; Palani HK; Venkatraman A; Alex AA; David S; Kumar SP; Radhakrishnan NR; Yasar M; Krishna S; Korula A; Kulkarni U; Janet NB; Balasubramanian P; Mathews V
Blood Adv; 2022 Jan; 6(2):652-663. PubMed ID: 34625794
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
Shepshelovich D; Oniashvili N; Parnes D; Klein A; Muchtar E; Yeshaya J; Aviram A; Rabizadeh E; Raanani P
Cancer Genet; 2015 Nov; 208(11):575-9. PubMed ID: 26471811
[TBL] [Abstract][Full Text] [Related]
16. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
17. Gelling Bodies: Understanding the Mechanisms Underlying Arsenic Trioxide Action.
Salomoni P
Cancer Discov; 2023 Dec; 13(12):2505-2506. PubMed ID: 38084094
[TBL] [Abstract][Full Text] [Related]
18. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Nasr R; de Thé H
Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
[TBL] [Abstract][Full Text] [Related]
19. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
